---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022315"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:25:58.759043+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q3 2022: First Sunosi revenue $16.8M, Auvelity launched, net loss $44.8M

## Summary
- Sunosi U.S. net sales $16.8M (first reported by Axsome); total revenues $16.8M vs $0 prior year.
- Net loss $44.8M ($1.07/share) vs $34.9M ($0.93) in Q3 2021; R&D $14.9M, SG&A $40.9M.
- Cash $227.5M (vs $86.5M Dec 2021); expects cash to fund operations into 2025.
- Auvelity launched Oct 20, 2022 for MDD; field force with prior psychiatry experience engaging prescribers.
- Pipeline: AXS-07 NDA resubmission Q3 2023; AXS-05 ACCORD topline Q4 2022; solriamfetol ADHD trial Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-022315
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/0000950170-22-022315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/axsm-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022315
- JSON: https://secwatch.observer/filing/0000950170-22-022315.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022315.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.
  - Period: the three months ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2022 and provided an update on the Company’s operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/0000950170-22-022315-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.